North Texas State University
Toxicological Evaluation for the Ocular Administration of Tolrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetes
Abstract
dc:descriptionAldose reductase inhibitors (ARI's) have been shown to attenuate or prevent several complications of diabetes in animals. Tolrestat is a potent and unique ARI from Ayerst Laboratories, New York, NY. The efficacy and toxicology of tolrestat via topical ocular administration was examined. Tolrestat effectively enhanced corneal reepithelialization and was efficacious in the prevention of cataracts in the streptozotocin-diabetic rat. Ocular tissues were examined by slit lamp biomicroscopy, scanning and transmission electron microscopy, and light microscopy. Liver and kidney tissue was also examined. The presence of tolrestat was confirmed in urine, feces, and eye specimens, and quantitated in serum. There was no evidence of local or systemic tolrestat induced toxicity. Tolrestat prevented cataract formation at less than one-third the reported oral dose and at approximately one-fiftieth the associated serum concentration in rats. ED-50 and TD-50 calculations indicate that tolrestat is a relatively safe drug by topical ocular administration.
Degree
thesis:*- Grantor dc:publisher
- North Texas State University
- Year dc:date
- 1987
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Carney, Gerald R.
- Contributors dc:contributor
-
- Wimbish, Gary Harold
- Carnes, James E.
- Harris, Ben G.
- Yorio, Thomas
Subjects
dc:subject × 7Rights
dc:rights- Statement dc:rights
-
- Public
- Carney, Gerald R.
- Copyright
- Copyright is held by the author, unless otherwise noted. All rights
- Language dc:language
- English
Identifiers
dc:identifier.*- Identifier
-
local-cont-no: 1002715271-Carney_Color
call-no: 379 N81d no.2765
untcat: b1416726
oclc: 18593230
ark: ark:/67531/metadc935757